The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review

Title:The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review

Volume: 14 Issue: 2

Author(s): Antonio Bruno, Paolo Morabito, Edoardo Spina and Maria Rosaria Muscatello

Affiliation:

Keywords: Antidepressants, efficacy, levomilnacipran extended release, major depressive disorder, safety, tolerability.

Abstract: Levomilnacipran, the more active enantiomer of the serotonin and norepinephrine reuptake inhibitor (SNRI) milnacipran, was recently approved in the US for the treatment of major depressive disorder (MDD). The drug was developed as an extended release (ER) capsule formulation to allow for once-daily administration, thereby improving patient adherence. This agent differs from other available SNRIs in having a greater potency for inhibition of norepinephrine relative to serotonin reuptake. The efficacy of levomilnacipran ER has been evaluated in seven randomised, double-blind clinical trials (one Phase II and four Phase III trials, and two long-term efficacy studies). These studies documented that levomilnacipran is generally more effective than placebo for the treatment of MDD in the short-term, whereas no firm evidence exists on long-term efficacy for relapse prevention. Preliminary evidence suggests that levomilnacipran ER may be effective in improving not only depressive symptoms but also symptoms related to functioning (social life, work, and family life). Short-and longer-term studies found that the rate of withdrawal from levomilnacipran therapy due to adverse events was rather low. Moreover the drug appeared to be generally well tolerated. The most common adverse effects included nausea, hyperhidrosis, constipation, tachycardia, palpitations, erectile dysfunction and ejaculation disorder. As hypertension or orthostatic hypotension may occur in a few patients, the cardiovascular safety of levomilnacipran needs to be more extensively investigated especially on long-term treatment. Additional active comparator trials evaluating efficacy, tolerability and cost-effectiveness are required to better define the role of levomilnacipran ER in the treatment of MDD in relation to currently available antidepressants including other SNRIs.

Cite this article as:

Bruno Antonio, Morabito Paolo, Spina Edoardo and Muscatello Rosaria Maria, The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review, Current Neuropharmacology 2016; 14 (2) . https://dx.doi.org/10.2174/1570159X14666151117122458